SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Aronex Pharma (ARNX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: The Dodgy Ticker who wrote (292)9/25/1999 8:56:00 AM
From: kendall harmon   of 320
 
ARNX--interesting post from physicianintexas on the YHOO thread:

As I said on 9/20: ATRAGEN for APL is a very minor player. The reason I am long is the hope that PLATAR and ATRAGEN will useful treatments for common cancers. See the company's press releases on the following. 9/9/99 - PLATAR Phase 2 trial expanded for renal cell cancer. 8/18/99 - ATRAGEN Phase 2 trial expanded for Prostate cancer. 5/17/99 - PLATAR's response rate for Mesothelioma is amazing. I quote: "A pathologic complete response based on biopsy and cytology was seen in 61% and 73% of the patients, respectively. In contrast, currently available therapies provide no more than a 10% to 15% response rate."

Go to this site: igm.nlm.nih.gov and search Medline for drug treatment of mesothelioma.

Here is what you will find.

Chest 1998 Jan;113(1 Suppl):66S-73S: Reviews treatment. No drug better than about 25%

Monaldi Arch Chest Dis 1998 Apr;53(2):236-40:
"The role of chemotherapy in the management of pleural mesothelioma still remains uncertain. The available data indicate that although 10-20% of patients are known to achieve on objective response to a number of chemotherapeutic agents, the impact on survival appears limited and improvement in the quality of life remains uncertain"

Semin Thorac Cardiovasc Surg 1997 Oct;9(4):361-6:
"In the Cancer and Leukemia Group B study, the response rate in patients with measurable disease was 24% for cisplatin and either mitomycin C and doxorubicin, the highest response rates reported for a cooperative group study."

Source: post.messages.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News